Universität zu Köln

Mairinger, Fabian D., Walter, Robert F. H., Werner, Robert, Christoph, Daniel C., Ting, Saskia ORCID: 0000-0003-1415-7714, Vollbrecht, Claudia ORCID: 0000-0002-0861-001X, Zarogoulidis, Konstantinos, Huang, Haidong, Li, Qiang, Schmid, Kurt W., Wohlschlaeger, Jeremias and Zarogoulidis, Paul (2014). Activation of Angiogenesis Differs Strongly Between Pulmonary Carcinoids and Neuroendocrine Carinomas and Is Crucial for Carcinoid Tumourgenesis. J. Cancer, 5 (6). S. 465 - 472. LAKE HAVEN: IVYSPRING INT PUBL. ISSN 1837-9664

Full text not available from this repository.

Abstract

Background: Lung cancer still remains the leading cause of cancer for men after prostate cancer and breast cancer for women. Angiogenesis is considered a major microenvironment modifier. Material and Methods: Demographic data and study design; The study is based on a collective of twenty representative specimens of each tumour entity (Typical Carcinoid, Atypical Carcinoid, Large-Cell Neuroendocrine Carcinoma, Small Cell Lung Cancer) for mRNA expression analysis. The following methods were performed: RNA Extraction and RNA Integrity Assessment, NanoString CodeSet Design and Expression Quantification, NanoString Data Processing and Statistical Analysis. Results: KDR rendered significant association to aggressiveness of the tumour and decreases with increasing malignancy (p=0.049). A decreased expression of HIF1A and KDR mRNA as associated with a higher risk of tumour invasion in vessels (HIF1A: p=0.034; KDR: p=0.029). FIGF and HIF1A expression levels are significantly associated with progression-free survival (FIGF: p=0.021; HIF1A: p=0.049). CRHR2 and FLT4 are stronger expressed in female than in male patients (CRHR2: p=0.024, FLT4: p=0.004). FIGF expression is still significant between LCNEC and SCLC (p=0.023). FLT4 and KDR show highly significant association to one of the analysed groups (FLT4: p=0.001; KDR: p=0.006). Additionally, HIF1A expression differs significantly between these focus cohorts (p=0.018). Conclusion: We should consider for clinical practice application which factors affect most the tumour growth and distal metastasis, thereafter investigate easy to administer drugs with low side effects. Probably a cluster system of therapy should be established where a drug targets simultaneously different pathways of the same origin.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Mairinger, Fabian D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Walter, Robert F. H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Werner, Robert UNSPECIFIED UNSPECIFIED UNSPECIFIED Christoph, Daniel C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ting, Saskia UNSPECIFIED orcid.org/0000-0003-1415-7714 UNSPECIFIED Vollbrecht, Claudia UNSPECIFIED orcid.org/0000-0002-0861-001X UNSPECIFIED Zarogoulidis, Konstantinos UNSPECIFIED UNSPECIFIED UNSPECIFIED Huang, Haidong UNSPECIFIED UNSPECIFIED UNSPECIFIED Li, Qiang UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmid, Kurt W. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wohlschlaeger, Jeremias UNSPECIFIED UNSPECIFIED UNSPECIFIED Zarogoulidis, Paul UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-449325
DOI:	10.7150/jca.9235
Journal or Publication Title:	J. Cancer
Volume:	5
Number:	6
Page Range:	S. 465 - 472
Date:	2014
Publisher:	IVYSPRING INT PUBL
Place of Publication:	LAKE HAVEN
ISSN:	1837-9664
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CELL LUNG-CANCER; TUMOR ANGIOGENESIS; OBSERVER VARIATION; PLUS ERLOTINIB; DOUBLE-BLIND; SURVIVAL; PLACEBO; CHEMOTHERAPY; METASTASIS; PREDICTORS Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/44932